Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Macular DiseasesRetinal Diseases

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Eye (Lond)

Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, Moll-Udina A, Bernal-Morales C, Sanchez-Vela L, Sararols-Ramsay L, Garay-Aramburu G, Arruabarrena C, García-Arumí J, Abraldes M, Ruiz-Moreno JM, Valldeperas X, Velázquez-Villoria D, Escobar-Barranco JJ, Gallego-Pinazo R, Figueroa MS, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J, from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group

doi: 10.1038/s41433-024-03322-8

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

Real-World Efficacy and Durability of Faricimab in Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

J Clin Med

Jeong A, Liang H, Baek SC, Sagong M

doi: 10.3390/jcm14155412

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Macular Diseases

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration

Acta Ophthalmol

Abu Ishkheidem I, Inci E, Breimer M, Silfverswärd ST, Zetterberg M, Grönlund MA

doi: 10.1111/aos.17590

Macular DiseasesRetinal Diseases

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Ophthalmol Retina

Ting Yap DW, Jyn Tan BK, Yi Chong KT, Wong TY, Gemmy Cheung CM

doi: 10.1016/j.oret.2025.01.010

Macular Diseases

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Ophthalmol Retina

Steinle NC, McCullough AJ, Silva FQ, Du W, Moini H, Singh RP

doi: 10.1016/j.oret.2024.12.018

Macular Diseases

Punctate Hyperfluorescence as a Favorable Predictive Factor for Treatment Response Following a Switch to Brolucizumab for Patients with Aflibercept-Refractory Neovascular Age-Related Macular Degeneration

J Clin Med

Kamao H, Goto K, Mizukawa K, Hiraki R, Miki A, Kimura S

doi: 10.3390/jcm14145141

Related content

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Real-World Efficacy and Durability of Faricimab in Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Punctate Hyperfluorescence as a Favorable Predictive Factor for Treatment Response Following a Switch to Brolucizumab for Patients with Aflibercept-Refractory Neovascular Age-Related Macular Degeneration